Immunovant (IMVT) Change in Account Payables (2019 - 2026)

Immunovant has reported Change in Account Payables for 8 years, with the latest figure at -$1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 41.45% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$10.3 million (down 195.96% YoY), and the FY2026 full-year result was -$10.3 million, down 195.96% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$1.3 million, down from $1.6 million in the prior quarter.
• The five-year high for Change in Account Payables was $25.0 million in Q2 2023, with the low at -$18.9 million in Q3 2023.
• Historically, Change in Account Payables has averaged $233117.6 across 5 years, with a median of -$260000.0 in 2024.
• The largest YoY upside for Change in Account Payables was 4312.76% in 2022 against a maximum downside of 2690.37% in 2022.
• Immunovant's Change in Account Payables stood at $6.5 million in 2022, then slumped by 157.23% to -$3.7 million in 2023, then surged by 92.98% to -$260000.0 in 2024, then surged by 701.15% to $1.6 million in 2025, then sank by 186.31% to -$1.3 million in 2026.
• The last three Change in Account Payables figures came in at -$1.3 million (Q1 2026), $1.6 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.